Unisa, University in Pretoria, South Africa

Geneva, Feb 11 The World Health Organization (WHO) has decided that potential benefits of the Oxford-AstraZeneca Covid-19 vaccine outweigh known and potential risks, amid concerns over its efficacy against the virus variant found in South Africa.The WHO Strategic Advisory Group of Experts on Immunization (SAGE) panel on Wednesday said the two-dose AstraZeneca vaccine efficacy tended to be higher when the interval between doses was within the four to 12 weeks range, reports Xinhua news agency.It also added that although preliminary analyses based on a small sample size in South Africa indicate a marked reduction in vaccine effectiveness against mild and moderate disease, it did not allow a specific assessment of vaccine efficacy against severe Covid-19.As indirect evidence is compatible with protection against severe Covid-19, the situation remains to be demonstrated in ongoing clinical trials and post-implementation evaluations.In view of this, WHO currently recommends the use of the AstraZeneca vaccine even if the variants are present in a country.Countries should conduct a benefit-risk assessment according to the local epidemiological situation, including the extent of circulating virus variants."We have made a recommendation that even if there is a reduction in the possibility of this vaccine having a full impact in its protection capacity, especially against severe disease, there is no reason not to recommend its use even in countries that have circulation of the variant," said SAGE chair Alejandro Cravioto at a briefing on Wednesday.Meanwhile, SAGE cautioned that as there are currently no efficacy or safety data for children or adolescents below the age of 18 years, vaccination of individuals below 18 years of age is not recommended until such data are available.South Africa said recently that the rollout of the AstraZeneca vaccine in the country would be temporarily put on hold until more "clinically efficacy information" of the vaccine against new Covid-19 variant becomes available.The decision came after a study showed that the AstraZeneca vaccine was less effective against the new variant found in South Africa. ( With inputs from IANS )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

UnisaFOLLOW

Unisa, Latest News

Addis Ababa, Feb 15 The number of confirmed Covid-19 cases on the African continent reached 3,740,297, the Africa ... ...

Addis Ababa, Feb 14 Africa's overall coronavirus caseload has increased to 3,731,343, while the death toll stood at 97,870, ... ...

Reeza Hendricks and Pite van Biljon both scored 42 runs as South Africa held their nerve throughout the innings to chase down Pakistan's total with 22 balls to spare in the second T20I on Saturday. ...

American actor Ashley Judd was taken to an ICU trauma ward in South Africa after suffering massive catastrophic injuries in an accident in the Congo. ...

Copenhagen, Feb 12 Recent declines in Covid-19 transmission and deaths in the European region in the past few weeks ... ...

Cricket South Africa (CSA) on Friday announced the expanded itinerary for Pakistan's limited-overs tour to South Africa in April that will wrap up the Proteas' international summer. ...

Johannesburg, Feb 12 South African President Cyril Ramaphosa has called for urgent actions to restore the country's pandemic-battered ... ...

Geneva, Feb 11 The World Health Organization (WHO) has decided that potential benefits of the Oxford-AstraZeneca Covid-19 vaccine outweigh ... ...